Prevalence of Rifampicin ResistantMycobacterium tuberculosis amongTreatment Failures and RelapsePatients Attending MogadishuTuberculosis Centers
Main Article Content
Abstract
Background: A resistance to rifampicin drugs has been a problem since the era of chemotherapy. After dramatic
outbreaks of multidrug-resistant tuberculosis (MDR-TB), including rifampicin in the early 1990s, resistance
became recognized as a global problem. A global total of 206,030 people with multidrug and/or rifampicin-resistant
TB (MDR/RR-TB) were detected and notified in 2019, a 10% increase from 186,883 in 2018. Globally, in 2019,
3.3% of new TB cases and 17.7% of previously treated cases had MDR/RR-TB. MDR/RR-TB still threatens
the inhabitants of high TB burden countries in Africa. Mogadishu, the capital of Somalia, represents one such
affected area. The most important risk factor for the development of rifampicin resistance-TB is previous anti-TB
therapy. Methods: This study was carried out to ascertain the prevalence of rifampicin resistance Mycobacterium
tuberculosis (MTB) among TB treatment failures and relapse patients attending Mogadishu TB centers. This was
a retrospective cross-sectional descriptive study of TB treatment failures and relapses that was based on secondary
data collected from TB patients who attended Mogadishu TB clinics. The prevalence of rifampicin resistance
in relation to age, gender, and geographic location was determined via the examination of this data. Results:
A total of 52 patients from Mogadishu TB clinics were recruited, including 28 treatment failure patients and 24
relapse patients. The average age was 31.77 years, with a range of 14–68 years. There were 18 female patients
(34.6%) and 34 male patients (65.4%). Rifampicin resistance MTB was found in 78.57 % of treatment failure
patients. The prevalence of relapse patients was 54.17%. Conclusion: The prevalence of rifampicin resistance
MTB in treatment failure and relapse patients was high. This study emphasizes the need to study the nation-wide
prevalence of rifampicin resistance MTB in previously treated patients.
Article Details
Section
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
This is an Open Access article distributed under the terms of the Attribution-Noncommercial 4.0 International License [CC BY-NC 4.0], which requires that reusers give credit to the creator. It allows reusers to distribute, remix, adapt, and build upon the material in any medium or format, for noncommercial purposes only.